You are here: Industry Insights > AML

News List

Researchers identify new genetic target for acute myeloid leukaemia pharmatimes
May 07, 2021
Researchers from the Wellcome Sanger Institute have identified a new genetic target, which is linked with poor prognosis, for the potential treatment of acute myeloid leukaemia (AML) – a type of blood cancer.
Actinium Completes Enrollment of Second Dose Cohort in Actimab-A Venetoclax Combination Trial americanpharmaceuticalreview
April 02, 2021
Actinium Pharmaceuticals announced that initial patient enrollment in the second dose cohort in the Phase 1 portion of the Actimab-A venetoclax Phase 1/2 combination trial in fit and unfit patients with relapsed or refractory Acute Myeloid Leukemia ...
ICR’s ‘resistance-busting’ drug advances into Phase I trial pharmatimes
March 19, 2021
The Institute of Cancer Research, London (ICR) has announced that its ‘resistance-busting’ drug EP0042 has entered a Phase I clinical trial in patients with cancers including acute myeloid leukaemia (AML).
Astellas Reports XOSPATA, Azacitidine Combination Did Not Meet Endpoint americanpharmaceuticalreview
December 23, 2020
Astellas Pharma announced that a Phase 3 trial of XOSPATA® (gilteritinib) plus azacitidine versus azacitidine alone in newly diagnosed FLT3 mutation-positive (FLT3mut+) acute myeloid leukemia (AML) patients who were ineligible for intensive induction ...
Syros acquires clinical-stage drug candidate for acute promyelocytic leukemia pharmaceutical-business-review
December 09, 2020
Syros Pharmaceuticals announced that it has acquired from Orsenix, LLC (Orsenix) all of its assets related to SY-2101, formerly known as ORH-2014, a novel oral form of arsenic trioxide (ATO).
Glycostem Initiates Trial to Evaluate oNKord for AML americanpharmaceuticalreview
December 08, 2020
Glycostem Therapeutics announced the opening of a phase I/IIa trial for its lead product oNKord® for the treatment of AML patients. The WiNK trial will enroll 33 AML patients at eight clinical sites based in five European countries.
I-Mab Accelerates Clinical Development of Anti-CD47 Monoclonal Antibody Lemzoparlimab in the US and China prnasia
December 07, 2020
I-Mab announced the advancement of clinical development of the highly differentiated anti-CD47 monoclonal antibody lemzoparlimab (also known as TJC4) in the US and China, achieving milestones as planned.
Breakthrough in AML Treatment: GoldenBiotech Reports New Drug Trial of Antroquinonol -Outperforms Listing Drugs in Relapsed Acute Myeloid Leukemia prnasia
November 27, 2020
Golden Biotechnology Corp. announces that its new drug Antroquinonol (HOCENA®) outperforms the other listing drugs for the treatment of relapsed AML (acute myeloid leukemia) patients in its Phase 2 clinical study conducted in Russia.
Actimab-A CLAG-M Trial for Relapsed or Refractory AML Achieves 100% Remission Rate americanpharmaceuticalreview
November 13, 2020
Actinium Pharmaceuticals announced 100% of evaluable patients in the third and planned final dose cohort of the Actimab-A CLAG-M Phase 1 trial being conducted at the Medical College of Wisconsin (MCW) achieved remission.
Vor Biopharma signs exclusive license pact with NCI for clinical-stage CD33 CAR-T expresspharma
November 12, 2020
It is currently being evaluated in a multi-site Phase 1/2 clinical trial in children and young adults with relapsed or refractory acute myeloid leukemia (AML).

Previous page 1 2 3 4 5 6 7 8 9 10 Next page